Month: October 2026
EDITORIAL: Illinois’ marijuana business is down, but not public health woes
The Chicago Tribune recently ran a story about a prominent state industry that’s enjoying booming popularity but, thanks to competition,…
The Tax Test On Cannabis Rescheduling And 280E
Federal marijuana rescheduling has barely taken effect, and the cannabis industry is already testing how far the change reaches.
Is JAZZ Stock Still a Smart Way to Play Medical Cannabis?
Jazz Pharmaceuticals offers a differentiated medical cannabis play, with Epidiolex sales growth and a diversified portfolio offset by pipeline setbacks…
What Makes Your Cannabis Business Buyable Right Now?
How attractive is my business to potential buyers in the current market? M&A experts offer 5 characteristics buyers are seeking for…
The Status of Federal Cannabis Rescheduling
On December 18, 2025 President Trump signed an executive order directing federal agencies to begin expediting the process of rescheduling…
La Mesa on track to hike cannabis tax to 5%
City leaders in La Mesa approved a 1% increase to the retail cannabis business tax rate, citing the potential revenue…
Canopy Growth vs. Tilray Brands: Which Cannabis Stock Is a Better Buy in 2026?
The cannabis industry is still finding its footing, but Tilray just posted record revenue with its beverage business turning profitable….
What Question 8 could mean for legal weed, taxes and safety in Massachusetts
A ballot measure to repeal recreational marijuana sales in Massachusetts could reshape the cannabis industry, shifting demand to medical marijuana.
Stacey Rusch broke a barrier in Virginia’s cannabis industry, and now she’s scaling her brand into new markets
Stacey Rusch spent years selling other companies’ products on QVC.
Acumen starts coverage of Auxly Cannabis Group stock at CAD 5.00
Acumen Capital began coverage of Auxly Cannabis Group with a CAD 5.00 price target on October 2, 2026, according to…



Recent Comments